Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

Global Gonorrhea Therapeutics Market 2020-2024

Published by TechNavio (Infiniti Research Ltd.) Product code 953211
Published Content info 120 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Gonorrhea Therapeutics Market 2020-2024
Published: July 29, 2020 Content info: 120 Pages
Description

Technavio has been monitoring the gonorrhea therapeutics market and it is poised to grow by $ 350.90 mn during 2020-2024 progressing at a CAGR of 5% during the forecast period. Our reports on gonorrhea therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the rising prevalence of disease, high-risk complications associated with gonorrhea and growing use of new diagnostic tests. In addition, rising prevalence of disease is anticipated to boost the growth of the market as well.

The gonorrhea therapeutics market market analysis includes therapy segment geographic landscapes

Technavio's ‘gonorrhea therapeutics market ’ is segmented as below:

By Therapy:

  • Monotherapy
  • Combination therapy

By Geographic Landscape:

  • North America
  • Europe
  • Asia
  • ROW

This study identifies the rising government initiatives to combat antibiotic resistance as one of the prime reasons driving the gonorrhea therapeutics market growth during the next few years. Also, advent of vaccine for prevention of gonorrhea and expedited partner therapy will lead to sizable demand in the market.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our gonorrhea therapeutics market covers the following areas:

  • Gonorrhea therapeutics market sizing
  • Gonorrhea therapeutics market forecast
  • Gonorrhea therapeutics market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading gonorrhea therapeutics market vendors that include AstraZeneca Plc, Bristol-Myers Squibb Co., Cipla Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Lupin Ltd., Merck & Co. Inc., Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.. Also, the gonorrhea therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Table of Contents
Product Code: IRTNTR44632

Table of Contents

Executive Summary

  • Market Overview

Market Landscape

  • Market ecosystem
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2019
  • Market outlook: Forecast for 2019 - 2024

Five Forces Analysis

  • Five forces summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Therapy

  • Market segments
  • Comparison by Therapy
  • Monotherapy - Market size and forecast 2019-2024
  • Combination therapy - Market size and forecast 2019-2024
  • Market opportunity by Therapy

Customer landscape

  • Customer landscape

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • Asia - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity by geography
  • Market drivers
  • Market challenges
  • Market trends

Vendor Landscape

  • Overview
  • Landscape disruption

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • AstraZeneca Plc
  • Bristol-Myers Squibb Co.
  • Cipla Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Lupin Ltd.
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

Exhibit

  • 1: Key Finding 1
  • 2: Key Finding 2
  • 3: Key Finding 3
  • 4: Key Finding 5
  • 5: Key Finding 6
  • 6: Key Finding 7
  • 7: Key Finding 8
  • 8: Parent market
  • 9: Market characteristics
  • 10: Offerings of vendors included in the market definition
  • 11: Market segments
  • 12: Global - Market size and forecast 2019 - 2024 ($ million)
  • 13: Global market: Year-over-year growth 2019 - 2024 (%)
  • 14: Five forces analysis 2019 & 2024
  • 15: Bargaining power of buyers
  • 16: Bargaining power of suppliers
  • 17: Threat of new entrants
  • 18: Threat of substitutes
  • 19: Threat of rivalry
  • 20: Market condition - Five forces 2019
  • 21: Other1 - Market share 2019-2024 (%)
  • 22: Comparison by Other1
  • 23: Monotherapy - Market size and forecast 2019-2024 ($ million)
  • 24: Monotherapy - Year-over-year growth 2019-2024 (%)
  • 25: Combination therapy - Market size and forecast 2019-2024 ($ million)
  • 26: Combination therapy - Year-over-year growth 2019-2024 (%)
  • 27: Market opportunity by Other1
  • 28: Customer landscape
  • 29: Market share by geography 2019-2024 (%)
  • 30: Geographic comparison
  • 31: North America - Market size and forecast 2019-2024 ($ million)
  • 32: North America - Year-over-year growth 2019-2024 (%)
  • 33: Europe - Market size and forecast 2019-2024 ($ million)
  • 34: Europe - Year-over-year growth 2019-2024 (%)
  • 35: Asia - Market size and forecast 2019-2024 ($ million)
  • 36: Asia - Year-over-year growth 2019-2024 (%)
  • 37: ROW - Market size and forecast 2019-2024 ($ million)
  • 38: ROW - Year-over-year growth 2019-2024 (%)
  • 39: Key leading countries
  • 40: Market opportunity by geography ($ million)
  • 41: Impact of drivers and challenges
  • 42: Vendor landscape
  • 43: Landscape disruption
  • 44: Industry risks
  • 45: Vendors covered
  • 46: Market positioning of vendors
  • 47: AstraZeneca Plc - Overview
  • 48: AstraZeneca Plc - Product and service
  • 49: AstraZeneca Plc - Key offerings
  • 50: AstraZeneca Plc - Key customers
  • 51: AstraZeneca Plc - Segment focus
  • 52: Bristol-Myers Squibb Co. - Overview
  • 53: Bristol-Myers Squibb Co. - Product and service
  • 54: Bristol-Myers Squibb Co. - Key offerings
  • 55: Bristol-Myers Squibb Co. - Key customers
  • 56: Bristol-Myers Squibb Co. - Segment focus
  • 57: Cipla Inc. - Overview
  • 58: Cipla Inc. - Business segments
  • 59: Cipla Inc. - Key offerings
  • 60: Cipla Inc. - Key customers
  • 61: Cipla Inc. - Segment focus
  • 62: F. Hoffmann-La Roche Ltd. - Overview
  • 63: F. Hoffmann-La Roche Ltd. - Business segments
  • 64: F. Hoffmann-La Roche Ltd. - Key offerings
  • 65: F. Hoffmann-La Roche Ltd. - Key customers
  • 66: F. Hoffmann-La Roche Ltd. - Segment focus
  • 67: GlaxoSmithKline Plc - Overview
  • 68: GlaxoSmithKline Plc - Business segments
  • 69: GlaxoSmithKline Plc - Key offerings
  • 70: GlaxoSmithKline Plc - Key customers
  • 71: GlaxoSmithKline Plc - Segment focus
  • 72: Lupin Ltd. - Overview
  • 73: Lupin Ltd. - Product and service
  • 74: Lupin Ltd. - Key offerings
  • 75: Lupin Ltd. - Key customers
  • 76: Lupin Ltd. - Segment focus
  • 77: Merck & Co. Inc. - Overview
  • 78: Merck & Co. Inc. - Business segments
  • 79: Merck & Co. Inc. - Key offerings
  • 80: Merck & Co. Inc. - Key customers
  • 81: Merck & Co. Inc. - Segment focus
  • 82: Pfizer Inc. - Overview
  • 83: Pfizer Inc. - Business segments
  • 84: Pfizer Inc. - Key offerings
  • 85: Pfizer Inc. - Key customers
  • 86: Pfizer Inc. - Segment focus
  • 87: Sun Pharmaceutical Industries Ltd. - Overview
  • 88: Sun Pharmaceutical Industries Ltd. - Business segments
  • 89: Sun Pharmaceutical Industries Ltd. - Key offerings
  • 90: Sun Pharmaceutical Industries Ltd. - Key customers
  • 91: Sun Pharmaceutical Industries Ltd. - Segment focus
  • 92: Teva Pharmaceutical Industries Ltd. - Overview
  • 93: Teva Pharmaceutical Industries Ltd. - Business segments
  • 94: Teva Pharmaceutical Industries Ltd. - Key offerings
  • 95: Teva Pharmaceutical Industries Ltd. - Key customers
  • 96: Teva Pharmaceutical Industries Ltd. - Segment focus
  • 97: Currency conversion rates for US$
  • 98: Research Methodology
  • 99: Validation techniques employed for market sizing
  • 100: Information sources
  • 101: List of abbreviations
Back to Top